Pancreatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pancreatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis – Drugs In Development, 2022, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.

Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatitis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 2, 16, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Global Markets Direct Report Coverage
Pancreatitis – Overview
Pancreatitis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pancreatitis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pancreatitis – Companies Involved in Therapeutics Development
AcelRx Pharmaceuticals Inc
Angion Biomedica Corp
Ariel Precision Medicine Inc
Beijing GeneCradle Technology Co Ltd
Bessor Pharma LLC
CalciMedica Inc
Centeer BioTherapeutics Ltd Co
Cypralis Ltd
D&D Pharmatech Co Ltd
Daewoong Pharmaceutical Co Ltd
DiaMedica Therapeutics Inc
Evive Biotech
GNT Pharma Co Ltd
GSK plc
Healx Ltd
HighTide Therapeutics Inc
JD Bioscience Inc
Johnson & Johnson
Kynos Therapeutics Ltd
Lamassu Pharma LLC
LipimetiX Development Inc
Mallinckrodt Plc
Panbela Therapeutics Inc
Path BioAnalytics Inc
PNB Vesper Life Science Pvt Ltd
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
SCM lifescience Co Ltd
Shionogi & Co Ltd
Pancreatitis – Drug Profiles
AAD-2004 – Drug Profile
AEM-28 – Drug Profile
AEM-2814 – Drug Profile
ANG-3070 – Drug Profile
APM-176 – Drug Profile
BP-1002 – Drug Profile
CBT-1430E – Drug Profile
CBT-1440G – Drug Profile
CC-4066 – Drug Profile
CM-4620 – Drug Profile
DM-300 – Drug Profile
Drug for Chronic Pancreatitis – Drug Profile
Drugs for Pancreatitis – Drug Profile
DWP-820S009 – Drug Profile
evinacumab – Drug Profile
F-652 – Drug Profile
GC-304 – Drug Profile
GM-10134 – Drug Profile
GSK-180 – Drug Profile
HTD-4010 – Drug Profile
LTX-608 – Drug Profile
MP-3964 – Drug Profile
naldemedine tosylate – Drug Profile
ND-07 – Drug Profile
pancrelipase DR – Drug Profile
PNB-081 – Drug Profile
RABI-767 – Drug Profile
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology – Drug Profile
SB-26 – Drug Profile
SBP-101 – Drug Profile
SCM-AGH – Drug Profile
SCM-AP – Drug Profile
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia – Drug Profile
Small Molecules to Inhibit Cyclophilin for Gastrointestinal and Musculoskeletal Disorders – Drug Profile
Small Molecules to Inhibit KMO for Pancreatitis – Drug Profile
Small Molecules to Inhibit Soluble Epoxide Hydrolase for Acute Pancreatitis – Drug Profile
TLY-012 – Drug Profile
Withaferin A – Drug Profile
Pancreatitis – Dormant Projects
Pancreatitis – Discontinued Products
Pancreatitis – Product Development Milestones
Featured News & Press Releases
Mar 17, 2022: Drug acceleration experts launch new biotech startup with eye on cancer treatments, global partnerships for patients
Mar 10, 2022: CalciMedica announces publication of peer-reviewed paper in the The Journal of Physiology; study supports development of CRAC channel inhibitors for acute pancreatitis
Sep 09, 2021: CalciMedica announces publication of preclinical data in Journal of Immunology further validating calcium release-activated calcium (CRAC) channels as drug targets for diseases of the airways
Jun 02, 2021: CalciMedica publishes positive data from phase 2a study of Auxora in patients with acute pancreatitis and announces first patients dosed in phase 2b study
Apr 20, 2021: Lamassu Pharma announces development of new pancreatitis treatment that advances understanding of fatty acids' role in COVID-19
Jul 14, 2020: Lamassu Pharma receives prestigious $1.5 million NIH SBIRP grant to support further development of its novel therapy for acute pancreatitis
Apr 30, 2020: CalciMedica expands clinical study to assess CM4620-IE in patients with critical COVID-19 pneumonia on high-flow oxygen therapy
Apr 09, 2020: FDA grants CalciMedica permission to begin dosing CM4620-IE in patients with severe covid-19 pneumonia under a newly opened IND
Jan 30, 2020: Theraly Fibrosis awarded $3.9 million SBIR phase II grant to support development of TLY012 for Chronic Pancreatitis
Nov 07, 2019: CalciMedica to present results of PD/PK study in acute pancreatitis patients for its CRAC channel inhibitor CM4620 at APA Annual Meeting
Oct 30, 2019: Henry Ford Hospital physician presents results from the initial patient study of calcimedica's CRAC channel inhibitor CM4620in acute pancreatitis at ACEP meeting
Sep 24, 2019: Theraly Fibrosis granted US Orphan Drug Designation for TLY012 for chronic pancreatitis
Mar 26, 2019: CalciMedica names life science veteran to its board of directors
Mar 19, 2019: CalciMedica to present study population profile from its initial patient study of its CRAC channel inhibitor CM4620 in Acute Pancreatitis at International Conference
Nov 01, 2018: Sun BioPharma to present results of new Pancreatitis study at American Pancreatic Association Meeting
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
List of Tables
Table 1: Number of Products under Development for Pancreatitis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Universities/Institutes, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Universities/Institutes, 2022
Table 8: Number of Products by Stage and Target, 2022
Table 9: Number of Products by Stage and Mechanism of Action, 2022
Table 10: Number of Products by Stage and Route of Administration, 2022
Table 11: Number of Products by Stage and Molecule Type, 2022
Table 12: Pancreatitis – Pipeline by AcelRx Pharmaceuticals Inc, 2022
Table 13: Pancreatitis – Pipeline by Angion Biomedica Corp, 2022
Table 14: Pancreatitis – Pipeline by Ariel Precision Medicine Inc, 2022
Table 15: Pancreatitis – Pipeline by Beijing GeneCradle Technology Co Ltd, 2022
Table 16: Pancreatitis – Pipeline by Bessor Pharma LLC, 2022
Table 17: Pancreatitis – Pipeline by CalciMedica Inc, 2022
Table 18: Pancreatitis – Pipeline by Centeer BioTherapeutics Ltd Co, 2022
Table 19: Pancreatitis – Pipeline by Cypralis Ltd, 2022
Table 20: Pancreatitis – Pipeline by D&D Pharmatech Co Ltd, 2022
Table 21: Pancreatitis – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Table 22: Pancreatitis – Pipeline by DiaMedica Therapeutics Inc, 2022
Table 23: Pancreatitis – Pipeline by Evive Biotech, 2022
Table 24: Pancreatitis – Pipeline by GNT Pharma Co Ltd, 2022
Table 25: Pancreatitis – Pipeline by GSK plc, 2022
Table 26: Pancreatitis – Pipeline by Healx Ltd, 2022
Table 27: Pancreatitis – Pipeline by HighTide Therapeutics Inc, 2022
Table 28: Pancreatitis – Pipeline by JD Bioscience Inc, 2022
Table 29: Pancreatitis – Pipeline by Johnson & Johnson, 2022
Table 30: Pancreatitis – Pipeline by Kynos Therapeutics Ltd, 2022
Table 31: Pancreatitis – Pipeline by Lamassu Pharma LLC, 2022
Table 32: Pancreatitis – Pipeline by LipimetiX Development Inc, 2022
Table 33: Pancreatitis – Pipeline by Mallinckrodt Plc, 2022
Table 34: Pancreatitis – Pipeline by Panbela Therapeutics Inc, 2022
Table 35: Pancreatitis – Pipeline by Path BioAnalytics Inc, 2022
Table 36: Pancreatitis – Pipeline by PNB Vesper Life Science Pvt Ltd, 2022
Table 37: Pancreatitis – Pipeline by Regeneron Pharmaceuticals Inc, 2022
Table 38: Pancreatitis – Pipeline by Samsung Bioepis Co Ltd, 2022
Table 39: Pancreatitis – Pipeline by SCM lifescience Co Ltd, 2022
Table 40: Pancreatitis – Pipeline by Shionogi & Co Ltd, 2022
Table 41: Pancreatitis – Dormant Projects, 2022
Table 42: Pancreatitis – Dormant Projects, 2022 (Contd..1)
Table 43: Pancreatitis – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Pancreatitis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings